Published in Gene Therapy Weekly, March 24th, 2005
As power shifts, life sciences firms are expected to gain in negotiations with Pharma companies and will assume a greater role in drug development, accelerating the pipeline of potentially more clinically effective drugs based upon individual genetic makeup.
These are findings in a report released by PricewaterhouseCoopers at the Biotechnology Industry Organizations (BIO) CEO & Investor Conference...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.